The Medicines Company (MDCO) : 5 brokerage houses believe that The Medicines Company (MDCO) is a Strong Buy at current levels. Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 5 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.
The Medicines Company (MDCO) : The highest level The Medicines Company (MDCO) is projected to reach is $65 for the short term and the lowest estimate is at $43. The consolidated price target from 5 rating analysts who initiate coverage on the stock is $51.6 and the possibility the share price can swing is $8.65.
For the current week, the company shares have a recommendation consensus of Buy. Also, Equity Analysts at the Citigroup maintains the rating on The Medicines Company (NASDAQ:MDCO). The brokerage firm has issued a Neutral rating on the shares. The Analysts at the ratings agency raises the price target from $43 per share to $44 per share. The rating by the firm was issued on August 1, 2016.
The Medicines Company (NASDAQ:MDCO): stock was range-bound between the intraday low of $37.12 and the intraday high of $38.74 after having opened at $38.19 on Wednesdays session. The stock finally closed in the red at $38.19, a loss of -2.25%. The stock remained in the red for the whole trading day. The total traded volume was 933,711 shares. The stock failed to cross $38.74 in Wednesdays trading. The stocks closing price on Thursday was $38.24.
The Medicines Company is a global biopharmaceutical company. The Companys marketed products are: Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Minocin (minocycline) for injection, Orbactiv (oritavancin), PreveLeak and Recothrom Thrombin topical (Recombinant). The Companys products in development include its registration stage product candidates and its research and development product candidates. It has a pipeline of acute and intensive care hospital products in development, including four registration stage product candidates for which the Company has submitted applications for regulatory approval in the United States, cangrelor, IONSYS (fentanyl iontophoretic transdermal system), Raplixa, formerly referred to as Fibrocaps, and RPX-602. The Companys four research and development product candidates include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. The Company also develops ABP-700, an intravenous anesthetic, which is in Phase I of clinical studies.